Viridian Therapeutics Posts $24.7 Million in Q3 Product Revenue, $101.2 Million Net Loss

Viridian Therapeutics reported Q3 2026 net product revenue of $24.7M and a net loss of $101.2M. Total revenue was $25.8M, with $955.2M in cash reserves. Lumvoa had over 100 patients on therapy. The company plans to submit a BLA for elegrobart in Q1 2027 and start a phase 1 trial for VRDN-292 in Q4 2026.

Original reporting
Published Nov 4, 2026, 12:13 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 12:22 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Viridian Therapeutics Posts $24.7 Million in Q3 Product Revenue, $101.2 Million Net Loss — source image
Decision brief

The 30-second read

$VRDNBearishMed
01

Why it matters

The earnings report reveals a substantial net loss despite a healthy cash runway, likely prompting short‑term downside while long‑term catalysts remain in the pipeline.

02

Market read

Primary earnings disclosure for a micro‑cap biotech; new financials and pipeline updates provide fresh trading data.

03

What to watch

CMS J‑code assignment and upcoming BLA filing for elegrobart may unlock future revenue.

Relevance 7/10Novelty 8/10Timing: after-hours release

Background

Viridian Therapeutics (VRDN) released its Q3 2026 earnings, highlighting product revenue, cash position, and pipeline milestones.

Company-level read

Ticker impact

$VRDNBearishHigh confidence
Context

Q3 2026 earnings disclosed net product revenue $24.7M, net loss $101.2M, cash $955.2M and pipeline updates.

Expected impact

downward pressure as investors price the large net loss

Evidence & confidence

The loss magnitude and modest revenue are worse than typical for a cash‑rich biotech, suggesting short‑term sell pressure.

Market effects

Biotech peers may face similar valuation pressure after a loss‑heavy earnings season.

US market, primarily Nasdaq biotech segment.

Limited to investors tracking US‑listed biotech stocks.

Counterpoint

Strong cash balance and pipeline progress could support a rebound if upcoming trials succeed.

Key entities

  • Viridian Therapeutics

    US‑listed biotech reporting Q3 results.

Related articles

$VRDNMedAI 8/10

Viridian Therapeutics gains long-term potential from extended-acting FcRn drug, Jefferies says

Jefferies highlights Viridian Therapeutics' (VRDN) VRDN-008 as a potential best-in-class FcRn inhibitor, with an extended half-life supporting eight-week dosing. Phase I results showed a 74% peak IgG reduction sustained for eight weeks. The company plans to start a registrational study in gMG in mid-2027, with potential approval by 2031. Jefferies maintains a $35 price target, excluding contributions from VRDN's broader pipeline.

$VRDNMedAI 8/10

Viridian Therapeutics Announces Positive VRDN-008 Phase 1 Results Supporting Potential Best-in-Class Profile with Every-8-Week Subcutaneous Dosing

Viridian Therapeutics, Inc.\DE (VRDN) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Viridian Therapeutics Announces Positive VRDN-008 Phase 1 Results Supporting Potential Best-in-Class Profile with Every-8-Week Subcutaneous Dosing - VRDN-008, a half-life extended FcRn inhibitor, demonstrated deep and sustained IgG reduction through 8 weeks after sub

$VRDNHighAI 8/10

Viridian reports phase 1 results for VRDN-008 autoimmune drug

Viridian Therapeutics (VRDN) reported phase 1 trial results for VRDN-008, showing a 74% reduction in IgG and a half-life of 15-18 days. No serious adverse events were observed. The company plans to start pivotal trials in 2027, targeting myasthenia gravis first. VRDN-008 will be administered using Enable Injections’ enFuse device, licensed exclusively by Viridian.